gutflix
GI learning, personalised

Summary

GHRELIN AND LEPTIN FOR NON-INVASIVE DIAGNOSIS OF ADVANCED ATROPHIC GASTRITIS AND INTESTINAL METAPLASIA

Nadine Koch

UEG Week Copenhagen 2023 | Poster

Stomach & H. Pylori

October 15, 2023

Adding serum Ghrelin and Leptin to GastroPanel® does not improve non-invasive detection of advanced gastric atrophy and intestinal metaplasia.

KEY POINTS

- In a cohort of 351 individuals with endoscopic and histologic characterization, the prevalence of OLGA/OLGIM stages 3/4 was 13.8%.
- GastroPanel® (Pepsinogen I, Pepsinogen II, Gastrin17, H. pylori antibodies) in a logistic regression model achieved AUC 0.676 with accuracy 0.833, sensitivity 0.882, specificity 0.333, PPV 0.932, and NPV 0.214 for detecting OLGA/OLGIM stages 3/4.
- Adding serum Ghrelin and Leptin to the model did not increase diagnostic power, yielding AUC 0.620 with accuracy 0.827, sensitivity 0.890, specificity 0.200, PPV 0.918, and NPV 0.154.
- The diagnostic value of GastroPanel® markers for detecting advanced gastric atrophy and intestinal metaplasia remains limited and is not improved by addition of Ghrelin and Leptin.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/fff98b48-743c-11ee-bff8-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.